Published in final edited form as:

Eur J Pediatr. 2019 May ; 178(5): 777–778. doi:10.1007/s00431-019-03349-0.

Magnetic resonance imaging characteristics of injection site reactions after long-term subcutaneous delivery of drisapersen

Rebecca J Willcocks¹, Sean C Forbes¹, Glenn A Walter², and Krista Vandenborne¹

¹:University of Florida, Department of Physical Therapy, 1225 Center Drive, Gainesville, Florida, USA

²:University of Florida, Department of Physiology and Functional Genomics, 1345 Center Drive, Gainesville, Florida, USA

Keywords

antisense oligonucleotide; Dixon imaging; lipoatrophy; subcutaneous fat

To the Editor,

We read with interest the report of Hilhorst et al. [1] describing prolonged injection site reactions following subcutaneous injection of drisapersen, an antisense oligonucleotide tested in a number of clinical trials in Duchenne muscular dystrophy (DMD). As part of a large natural history study, ImagingDMD, we have acquired MR images of these areas of sclerosis and lipoatrophy over time, and wish to share the progressive subcutaneous changes in signal intensity we observed using several magnetic resonance imaging methods.

MR imaging revealed several attributes of pathology in these images. Chemical shift-encoded imaging, sometimes called Dixon imaging, reveals numerous aspects of pathology (Figures 1a and 1b), capturing the lipoatrophy (seen as decreased subcutaneous fat thickness) and fluid accumulation (seen as increased signal on Dixon water maps) as well as markedly decreased fat content within the affected region (seen as areas of decreased signal on Dixon fat maps). This area likely includes both sclerosis and fluid changes. Notably, all these characteristics persist or worsen over time, even several years after cessation of drisapersen administration (Figure 1c). In keeping with the report of Hilhorst et al., lipoatrophy is particularly striking in the upper extremity (Figure 1d). Additionally, T₂ weighted MR imaging revealed areas of clear hyperintensity within the subcutaneous fat, which indicate fluid accumulation consistent with inflammation and associated edema (Figure 1e).

These images provide additional insight into the characteristics of the persistent injection site reactions following drisapersen treatment and demonstrate the ability of MRI to capture multiple aspects of this pathological process. We hope that by sharing them with the

community we can assist in the discussion of the management of this phenomenon and prevention of this effect in future trials of antisense oligonucleotides.

Acknowledgements:

We thank the participants and their families. This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institute of Neurological Disorders and Stroke R01AR056973 (www.niams.nih.gov/) and the Wellstone Muscular Dystrophy Center U54R052646 (www.wellstonemdcenters.nih.gov/)

Abbreviations:

DMD	Duchenne muscular dystrophy
-----	-----------------------------

References

1. Hilhorst N, Spanoudi-Kitrimi I, Goemans N, Morren MA (2018) Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. *Eur J Pediatr*

Fig 1. MR characteristics of lesions in subcutaneous fat.

1a. Chemical shift-based fat maps of the thigh (3 axial slices separated by ~12mm) showing areas of hypointensity (indicated with a * next to the affected area) in the subcutaneous fat adjacent to the vastus lateralis and rectus femoris muscles, which may be the result of edema, inflammation, or fibrosis

1b. Chemical shift-based water maps from the same locations as 1A, showing marked hyperintensity in the area of the lesion in subcutaneous fat (*)

1c. Over time, the inflammation or edema in the subcutaneous fat persists, while the lipoatrophy (*) progresses. Note that drisapersen administration was halted between the first and second visit, but the lesion continues to worsen over time

1d. Axial chemical shift-based water maps covering ~5.5 cm of the upper arm of a treated patient ~2.5 years after cessation of treatment, and showing the pronounced lipoatrophy (*) over the triceps brachii muscle affecting an area 5–7 cm in diameter

1e. T₂ changes in the subcutaneous fat indicative of inflammation or edema can be easily seen using T₂ weighted imaging (indicated with a * next to the affected area). This image was taken prior to the cessation of administration of drisapersen